NS-2359 explained

NS-2359 (GSK-372475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,^[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.^[2] The results did not support further effort by the company.^[1] NS-2359 was also in clinical trials for the treatment of ADHD,^[3] phase II having been completed in 2007. A phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.

See also

• Tesofensine

Notes and References

1. Web site: NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression . NeuroSearch . 2009-06-20 . 2016-03-04 . https://web.archive.org/web/20160304000739/https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=313018&messageId=372903 . live .
2. Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E . Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials . Journal of Psychopharmacology . 26 . 5 . 653–62 . May 2012 . 22048884 . 10.1177/0269881111424931 . 9365152 .
3. Wilens TE, Klint T, Adler L, West S, Wesnes K, Graff O, Mikkelsen B . A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD . Behavioral and Brain Functions . 4 . 24 . June 2008 . 18554401 . 2442604 . 10.1186/1744-9081-4-24 . free .